Researcher
Christophe Deroose
- Disciplines:Medical imaging and therapy, Medicinal products
Affiliations
- Nuclear Medicine & Molecular Imaging (Division)
Member
From1 Oct 2002 → Today
Projects
1 - 10 of 30
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals for pancreatic cancerFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- '213Bi-188Ready' Improved Theranostics with Bismuth-213 and Rhenium-188From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Targeted alpha therapy of pancreatic tumors in a theranostic settingFrom1 Oct 2022 → TodayFunding: BOF - projects, Fund Recuperation Fiscal Exemption
- IMAGINATION : IMAGing bIomarkers for diagNosis, therAnosTIcs and drug develOpmeNtFrom1 Oct 2022 → TodayFunding: IOF - mandates
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals targeting CXCR4From10 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- 18F-PSMA-1007 PET/MR imaging, quantification and radiomics in the primary staging of prostate cancer and response prediction after neoadjuvant hormonal therapyFrom1 Aug 2021 → TodayFunding: FWO Strategic Basic Research Grant
- New Strategies in Locoregional, Minimally Invasive Therapy of Liver CancerFrom1 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
Publications
31 - 40 of 223
- The role of microscopic bone marrow examination and [123I]MIBG scintigraphy in detection of bone marrow involvement in patients with neuroblastoma(2022)
Authors: Thomas Tousseyn, Christophe Deroose, Anne Uyttebroeck, Nancy Boeckx
Pages: 868 - 873 - Simplified Semi-Quantification of [F-18]PSMA-1007 Uptake in Treatment-Naive Primary Prostate Cancer(2022)
Authors: Michel Koole, Wouter Everaerts, Steven Joniau, Christophe Deroose, Karolien Goffin
Pages: S505 - S506 - Development and external validation of a PET radiomic model for prognostication of head and neck cancer(2022)
Authors: Christophe Deroose
Pages: S20 - S21 - Metabolic Tumor Volume Improves Outcome Prediction in Untreated Mantle Cell Lymphoma(2022)
Authors: Vibeke Vergote, Gregor Verhoef, Ann Janssens, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe Deroose
Pages: S214 - S215 - Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study(2022)
Authors: Lien Smets, Albert Wolthuis, Jeroen Dekervel, Christophe Deroose, Xavier Sagaert, Karin Haustermans
Pages: 113 - 120 - 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals(2022)
Authors: Stephen Ahenkorah, Christopher Cawthorne, Christophe Deroose, Thomas Cardinaels, Willy Gsell, Guy Bormans, Frederik Cleeren
Pages: 5971 - 5985 - Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature(2022)
Authors: Annouschka Laenen, Birgit Weynand, Christophe Dooms, Walter De Wever, Karolien Goffin, Johan Vansteenkiste, Koen Van Laere, Paul De Leyn, Kristiaan Nackaerts, Christophe Deroose
- Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors(2022)
Authors: Elin Pauwels, Kristof Baete, Paul Clement, Kristiaan Nackaerts, Chris Verslype, Christophe Deroose
- Increased Uptake of 18F-PSMA-1007 in Corpus Luteum Demonstrated by PET/CT(2022)
Authors: Karolien Goffin, Koen Van Laere, Christophe Deroose
Pages: E331 - E332 - ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours(2022)
Authors: Christophe Deroose